GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled 

Company on track to report interim biomarker data from the first 12 patients imminently

Read more at globenewswire.com